The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: A Mayo cohort of 796 patients with extended follow-up after surgical resection

Mayo Clinic Proceedings

Volumn 85, Issue 12, 2010, Pages 1080-1089

  Yoon, Harry H ^a   Khan, Maliha ^a   Shi, Qian ^a   Cassivi, Stephen D ^a   Wu, Tsung Teh ^a   Quevedo, J Fernando ^a   Burch, Patrick A ^a   Sinicrope, Frank A ^a   Diasio, Robert B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIA; COHORT ANALYSIS; DISEASE FREE SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; HUMAN; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOLOGY; PREOPERATIVE CARE; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; SIGNET RING CARCINOMA; UNIVARIATE ANALYSIS;

EID: 78650134055     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0421     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66.
2. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142-146. (Pubitemid 40277094)
3. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241-2252.
4. Suntharalingam M, Moughan J, Coia LR, et al. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2003;56(4):981-987.
5. Yoon HH, Gibson MK. Combined-modality therapy for esophageal and gastroesophageal junction cancers. Curr Oncol Rep. 2007;9(3):184-192.
6. Kamangar F, Chow WH, Abnet CC, Dawsey SM. Environmental causes of esophageal cancer. Gastroenterol Clin North Am. 2009;38(1):27-57, vii.
7. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010;10(2):87-101.
8. Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198(2):205-211. (Pubitemid 38175235)
9. de Manzoni G, Pedrazzani C, Pasini F, et al. Pattern of recurrence after surgery in adenocarcinoma of the gastro-oesophageal junction. Eur J Surg Oncol. 2003;29(6):506-510. (Pubitemid 37009967)
10. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100(16):1184-1187.
11. Rice TW, Rusch VW, Apperson-Hansen C, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009;22(1):1-8.
12. Braiteh F, Correa AM, Hofstetter WL, et al. Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy. Cancer. 2009;115(19):4450-4458.
13. Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am. 2006;15(4):751-764. (Pubitemid 44499032)
14. Tomaszek S, Cassivi SD. Esophagectomy for the treatment of esophageal cancer. Gastroenterol Clin North Am. 2009;38(1):169-181, x.
15. Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974;19(6):716-723.
16. Lin D, Wei L, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80(3):557-572.
17. Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer. 2002;95(7):1434-1443.
18. Rice TW, Blackstone EH, Adelstein DJ, et al. N1 esophageal carcinoma: the importance of staging and downstaging. J Thorac Cardiovasc Surg. 2001;121(3):454-464. (Pubitemid 32230213)
19. Chirieac LR, Swisher SG, Correa AM, et al. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res. 2005;11(6):2229-2236.
20. Lagarde SM, ten Kate FJ, de Boer DJ, Busch OR, Obertop H, van Lanschot JJ. Extracapsular lymph node involvement in node-positive patients with adenocarcinoma of the distal esophagus or gastroesophageal junction. Am J Surg Pathol. 2006;30(2):171-176.
21. Gaast AV, Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study [abstract 4004]. J Clin Oncol. 2010;28(suppl):15s.
22. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8(3):226-234. (Pubitemid 46291702)
23. Jougon JB, Ballester M, Duffy J, et al. Esophagectomy for cancer in the patient aged 70 years and older. Ann Thorac Surg. 1997;63(5):1423-1427. (Pubitemid 27239737)
24. Sabel MS, Smith JL, Nava HR, Mollen K, Douglass HO, Gibbs JF. Esophageal resection for carcinoma in patients older than 70 years. Ann Surg Oncol. 2002;9(2):210-214. (Pubitemid 34259710)
25. Portale G, Peters JH, Hsieh CC, et al. Esophageal adenocarcinoma in patients < or = 50 years old: delayed diagnosis and advanced disease at presentation. Am Surg. 2004;70(11):954-958.
26. Ellis FH Jr, Williamson WA, Heatley GJ. Cancer of the esophagus and cardia: does age influence treatment selection and surgical outcomes? J Am Coll Surg. 1998;187(4):345-351.
27. Rice TW, Rusch VW, Ishwaran H, Blackstone EH; Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer. 2010;116(16):3763-3773.
28. Khan OA, Alexiou C, Soomro I, Duffy JP, Morgan WE, Beggs FD. Pathological determinants of survival in node-negative oesophageal cancer. Br J Surg. 2004;91(12):1586-1591. (Pubitemid 39619922)
29. Westerterp M, Koppert LB, Buskens CJ, et al. Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch. 2005;446(5):497-504. (Pubitemid 40884282)
30. Rice TW, Blackstone EH, Rybicki LA, et al. Refining esophageal cancer staging. J Thorac Cardiovasc Surg. 2003;125(5):1103-1113.
31. Ellis FH Jr, Heatley GJ, Balogh K. Proposal for improved staging criteria for carcinoma of the esophagus and cardia. Eur J Cardiothorac Surg. 1997;12(3):361-364. (Pubitemid 27397972)
32. Holscher AH, Bollschweiler E, Bumm R, Bartels H, Hofler H, Siewert JR. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery. 1995;118(5):845-855.
33. Nigro JJ, Hagen JA, DeMeester TR, et al. Prevalence and location of nodal metastases in distal esophageal adenocarcinoma confined to the wall: implications for therapy. J Thorac Cardiovasc Surg. 1999;117(1):16-23.
34. Pennathur A, Farkas A, Krasinskas AM, et al. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg. 2009;87(4):1048-1054.
35. Ancona E, Rampado S, Cassaro M, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 2008;15(11):3278-3288.
36. Rice TW, Zuccaro G Jr, Adelstein DJ, Rybicki LA, Blackstone EH, Goldblum JR. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg. 1998;65(3):787-792.
37. Lagarde SM, ten Kate FJ, Reitsma JB, Busch OR, van Lanschot JJ. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 2006;24(26):4347-4355.
38. Bernards R, Weinberg RA. A progression puzzle. Nature. 2002;418(6900):823.
39. Chou SH, Chuang HY, Huang MF, Lee CH, Yau HM. A prospective comparison of transthoracic and transhiatal resection for esophageal carcinoma in Asians. Hepatogastroenterology. 2009;56(91-92):707-710.
40. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246(6):992-1000, discussion 1000-1001.
41. Chu KM, Law SY, Fok M, Wong J. A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg. 1997;174(3):320-324. (Pubitemid 27415363)
42. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Longterm results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062-5067.
43. Kelsen DP, Winter KA, Gunderson LL, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25(24):3719-3725.